Institute for Experimental Surgery, Rostock University Medical Center, Schillingallee 69a, 18059 Rostock, Germany.
Int J Mol Sci. 2018 Nov 27;19(12):3770. doi: 10.3390/ijms19123770.
Yes-associated protein, a core regulator of the Hippo-YAP signaling pathway, plays a vital role in inhibiting apoptosis. Thus, several studies and reviews suggest that yes-associated protein is a good target for treating cancer. Unfortunately, more and more evidence demonstrates that this protein is also an essential contributor of p73-mediated apoptosis. This questions the concept that yes-associated protein is always a good target for developing novel anti-cancer drugs. Thus, the aim of this review was to evaluate the clinical relevance of yes-associated protein for cancer pathophysiology. This review also summarized the molecules, processes and drugs, which regulate Hippo-YAP signaling and discusses their effect on apoptosis. In addition, issues are defined, which should be addressed in the future in order to provide a solid basis for targeting the Hippo-YAP signaling pathway in clinical trials.
Yes 相关蛋白是 Hippo-YAP 信号通路的核心调节因子，在抑制细胞凋亡中发挥着重要作用。因此，有几项研究和综述表明，Yes 相关蛋白是治疗癌症的一个很好的靶点。不幸的是，越来越多的证据表明，这种蛋白也是 p73 介导的细胞凋亡的一个重要贡献者。这就质疑了 Yes 相关蛋白始终是开发新型抗癌药物的良好靶点的概念。因此，本综述的目的是评估 Yes 相关蛋白在癌症病理生理学中的临床相关性。本综述还总结了调节 Hippo-YAP 信号的分子、过程和药物，并讨论了它们对细胞凋亡的影响。此外，还确定了未来需要解决的问题，以便为 Hippo-YAP 信号通路在临床试验中的靶向治疗提供坚实的基础。
